Patents by Inventor Jianfeng Xin

Jianfeng Xin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • OXAZEPINE COMPOUNDS AND USES THEREOF IN THE TREATMENT OF CANCER
    Publication number: 20240383915
    Abstract: Provided herein are acyclic oxazepinyl compounds useful in the treatment on cancers.
    Type: Application
    Filed: April 6, 2022
    Publication date: November 21, 2024
    Applicant: Genentech, Inc.
    Inventors: Lewis J. GAZZARD, Samantha Alyson GREEN, Elizabeth H. KELLEY, Matthew Leo LANDRY, Sushant MALHOTRA, Benjamin David RAVETZ, Michael SIU, Jack Alexander TERRETT, BinQing WEI, Steven DO, Yun-Xing CHENG, Limin CHENG, Jianfeng XIN, Mingtao HE, Guosheng WU, Yinlei SUN, Cheng SHAO, Aijun LU, Yulai ZHANG
  • Fused ring compounds
    Patent number: 12084429
    Abstract: This invention pertains to fused ring compounds of Formula (I), as further detailed herein, which are used for the inhibition of Ras proteins, as well as compositions comprising these compounds and methods of treatment by their administration.
    Type: Grant
    Filed: December 17, 2021
    Date of Patent: September 10, 2024
    Assignee: Genentech, Inc.
    Inventors: Sushant Malhotra, Jianfeng Xin, Steven Do, Jack Terrett
  • FUSED RING COMPOUNDS
    Publication number: 20230089126
    Abstract: This invention pertains to fused ring compounds of Formula (I), as further detailed herein, which are used for the inhibition of Ras proteins, as well as compositions comprising these compounds and methods of treatment by their administration.
    Type: Application
    Filed: December 17, 2021
    Publication date: March 23, 2023
    Inventors: Sushant Malhotra, Jianfeng Xin, Steven Do, Jack Terrett
  • TETRACYCLIC OXAZEPINE COMPOUNDS AND USES THEREOF
    Publication number: 20220281893
    Abstract: Provided herein are tetracyclic oxazepinyl compounds useful in the treatment on cancers.
    Type: Application
    Filed: February 7, 2022
    Publication date: September 8, 2022
    Applicant: Genentech, Inc.
    Inventors: Lewis J. GAZZARD, Samantha Alyson GREEN, Matthew Leo LANDRY, Sushant MALHOTRA, Michael SIU, Steven DO, Yun-Xing CHENG, Limin CHENG, Jianfeng XIN, Mingtao HE
  • (4-hydroxypyrrolidin-2-yl)-heterocyclic compounds and methods of use thereof
    Patent number: 11242344
    Abstract: The present disclosure relates to bifunctional compounds, which can be used as modulators of targeted ubiquitination. In particular, the present disclosure is directed to compounds which contain on one end a VHL ligand moiety, which binds to the VHL E3 ubiquitin ligase, and on the other end a moiety that binds a target protein such that degradation of the target protein/polypeptide is effectuated. Also disclosed are VHL ligands.
    Type: Grant
    Filed: April 24, 2020
    Date of Patent: February 8, 2022
    Assignee: Genentech, Inc.
    Inventors: Nicole Blaquiere, Peter Dragovich, Lewis J. Gazzard, Thomas Pillow, Steven T. Staben, Binqing Wei, Jianfeng Xin
  • Fused ring compounds
    Patent number: 11236068
    Abstract: This invention pertains to fused ring compounds of Formula (I), as further detailed herein, which are used for the inhibition of Ras proteins, as well as compositions comprising these compounds and methods of treatment by their administration.
    Type: Grant
    Filed: November 8, 2019
    Date of Patent: February 1, 2022
    Assignee: Genentech, Inc.
    Inventors: Sushant Malhotra, Jianfeng Xin, Steven Do, Jack Terrett
  • (4-HYDROXYPYRROLIDIN-2-YL)-HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF
    Publication number: 20210309660
    Abstract: The present disclosure relates to bifunctional compounds, which can be used as modulators of targeted ubiquitination. In particular, the present disclosure is directed to compounds which contain on one end a VHL ligand moiety, which binds to the VHL E3 ubiquitin ligase, and on the other end a moiety that binds a target protein such that degradation of the target protein/polypeptide is effectuated. Also disclosed are VHL ligands.
    Type: Application
    Filed: April 24, 2020
    Publication date: October 7, 2021
    Inventors: Nicole Blaquiere, Peter Dragovich, Lewis J. Gazzard, Thomas Pillow, Steven T. Staben, Binqing Wei, Jianfeng Xin
  • FUSED RING COMPOUNDS
    Publication number: 20210230142
    Abstract: This invention pertains to fused ring compounds of Formula (I), as further detailed herein, which are used for the inhibition of Ras proteins, as well as compositions comprising these compounds and methods of treatment by their administration.
    Type: Application
    Filed: November 8, 2019
    Publication date: July 29, 2021
    Inventors: Sushant Malhotra, Jianfeng Xin, Steven Do, Jack Terrett
  • FUSED RING COMPOUNDS
    Publication number: 20200181118
    Abstract: This invention pertains to fused ring compounds of Formula (I), as further detailed herein, which are used for the inhibition of Ras proteins, as well as compositions comprising these compounds and methods of treatment by their administration.
    Type: Application
    Filed: November 8, 2019
    Publication date: June 11, 2020
    Inventors: Sushant Malhotra, Jianfeng Xin